Skip to content
LIGAND PHARMACEUTICALS INC (LGND) Insider Trading
Home / Companies / LGND LGN
LIGAND PHARMACEUTICALS INC (LGND) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest LGND Insider Trades
About LIGAND PHARMACEUTICALS INC (LGND) Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Headquarters SAN DIEGO, CA
Employees 47
Listed 1994
Exchange XNAS https://www.ligand.com SEC filings for LGND on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 36 71,976 $20.08M Grant or award 14 26,418 Option exercise 24 117,848
LGND Insider Transactions (Form 4) 87 57 Form 4 filings on record, the earliest from Dec 2, 2024, newest first. Filing history page 2 of 2.
Date Insider Transaction Security Shares Price Value Mar 3, 2026 SS Stephen L. Sabba - Director Option exercise Non- Qualified Stock Option (right to buy) 2,034
Recent LGND Form 8-K Filings 5
Recent LGND Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 12, 2026 OCTAVIO ESPINOZA Officer 31,641 $9.14M View on EDGAR Aug 12, 2026 Jason Haas Director
LGND Insider Trading - FAQ
What is the latest insider trade for LGND? LIGAND PHARMACEUTICALS INC (LGND) had 17 insider filings in the last 90 days, with the most recent on 2026-08-14. The full record for LGND runs to 57 Form 4 filings, the earliest from 2024-12-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying LGND stock? No insider purchases of LGND were filed in the last 90 days.
How many insiders are selling LGND stock? 36 insider sales of LGND were filed in the last 90 days, totaling $20.08M.
Where can I see LGND SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks LGND Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow LGND insider buys? Create a free InsiderAlpha account and press Watch on this page to add LGND to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track LGND insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free $2.09M
Market cap $5.59B
P/E ratio 29.60
Dividend yield -
Average volume 350.3K
52 week high $326.63
52 week low $158.40
Today's high $284.00
Today's low $277.36
Open $283.70
Volume 127.7K
Previous close $284.52
Shares outstanding 19.94M Market cap
$5.59B
47 employees
LGND Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 36 sales totaling $20.08M.
Most-Active LGND Insiders - Last 90 Days 10 Tax withholding / forfeiture 1 182
Other acquisition / disposition 3 281
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Mar 3, 2026 SS Stephen L. Sabba - Director Option exercise Common Stock 2,034 $69.51 $141K
Mar 3, 2026 SS Stephen L. Sabba - Director Open-market sale Common Stock 2,034 $201.50 $410K
Mar 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 41 $200.40 $8K
Mar 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 83 $201.65 $17K
Mar 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 50 $202.54 $10K
Mar 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 42 $203.57 $9K
Mar 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 47 $197.14 $9K
Mar 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 204 $199.69 $41K
Feb 14, 2026 AR Andrew Reardon - Officer Grant or award Common Stock 6,928 $0.00 -
Feb 14, 2026 AR Andrew Reardon - Officer Tax withholding / forfeiture Common Stock 3,211 $183.83 $590K
Feb 14, 2026 AR Andrew Reardon - Officer Grant or award Common Stock 8,810 $0.00 -
Feb 14, 2026 AR Andrew Reardon - Officer Tax withholding / forfeiture Common Stock 4,083 $183.83 $751K
Feb 15, 2026 AR Andrew Reardon - Officer Tax withholding / forfeiture Common Stock 593 $183.83 $109K
Feb 15, 2026 AR Andrew Reardon - Officer Tax withholding / forfeiture Common Stock 801 $183.83 $147K
Feb 15, 2026 AR Andrew Reardon - Officer Tax withholding / forfeiture Common Stock 992 $183.83 $182K
Feb 14, 2026 OE Octavio Espinoza - Officer Tax withholding / forfeiture Common Stock 4,483 $183.83 $824K
Feb 15, 2026 OE Octavio Espinoza - Officer Tax withholding / forfeiture Common Stock 1,026 $183.83 $189K
Feb 15, 2026 OE Octavio Espinoza - Officer Tax withholding / forfeiture Common Stock 1,223 $183.83 $225K
Feb 15, 2026 OE Octavio Espinoza - Officer Tax withholding / forfeiture Common Stock 1,270 $183.83 $233K
Feb 14, 2026 OE Octavio Espinoza - Officer Tax withholding / forfeiture Common Stock 3,761 $183.83 $691K
Feb 14, 2026 TD Todd C. Davis - Officer Grant or award Common Stock 20,782 $0.00 -
Feb 14, 2026 TD Todd C. Davis - Officer Tax withholding / forfeiture Common Stock 8,178 $183.83 $1.50M
Feb 14, 2026 TD Todd C. Davis - Officer Grant or award Common Stock 39,644 $0.00 -
Feb 14, 2026 TD Todd C. Davis - Officer Tax withholding / forfeiture Common Stock 15,600 $183.83 $2.87M
Feb 15, 2026 TD Todd C. Davis - Officer Tax withholding / forfeiture Common Stock 2,039 $183.83 $375K
Feb 15, 2026 TD Todd C. Davis - Officer Tax withholding / forfeiture Common Stock 4,255 $183.83 $782K
Feb 15, 2026 TD Todd C. Davis - Officer Tax withholding / forfeiture Common Stock 2,805 $183.83 $516K
Feb 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 39 $191.00 $7K
Feb 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 1 $192.18 $192
Feb 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 23 $195.61 $4K
Feb 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 381 $196.36 $75K
Feb 2, 2026 JK John W. Kozarich - Director Open-market sale Common Stock 23 $197.20 $5K
Dec 12, 2025 OE Octavio Espinoza - Officer Open-market sale Common Stock 1,804 $188.31 $340K
Dec 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 92 $193.86 $18K
Dec 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 179 $194.76 $35K
Dec 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 47 $195.80 $9K
Dec 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 4 $196.35 $785
Dec 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 92 $197.72 $18K
Dec 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 23 $199.22 $5K
Dec 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 30 $200.02 $6K
Nov 7, 2025 NG Nancy Ryan Gray - Director Option exercise Non-Qualified Stock Option (right to buy) 3,015 $0.00 -
Nov 7, 2025 NG Nancy Ryan Gray - Director Option exercise Common Stock 3,556 $66.19 $235K
Nov 7, 2025 NG Nancy Ryan Gray - Director Open-market sale Common Stock 3,556 $205.45 $731K
Nov 7, 2025 NG Nancy Ryan Gray - Director Option exercise Common Stock 3,015 $73.57 $222K
Nov 7, 2025 NG Nancy Ryan Gray - Director Open-market sale Common Stock 3,015 $205.45 $619K
Nov 7, 2025 NG Nancy Ryan Gray - Director Option exercise Non-Qualified Stock Option (right to buy) 3,556 $0.00 -
Nov 7, 2025 JL John L. Lamattina - Director Option exercise Non-Qualified Stock Option (right to buy) 2,145 $0.00 -
Nov 7, 2025 JL John L. Lamattina - Director Option exercise Non-Qualified Stock Option (right to buy) 2,034 $0.00 -
Nov 7, 2025 JL John L. Lamattina - Director Open-market sale Common Stock 2,145 $205.45 $441K
Nov 7, 2025 JL John L. Lamattina - Director Open-market sale Common Stock 2,034 $205.45 $418K
Nov 3, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 49 $190.26 $9K
Nov 3, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 207 $191.25 $40K
Nov 3, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 127 $192.38 $24K
Nov 3, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 84 $189.00 $16K
Oct 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 24 $177.60 $4K
Oct 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 196 $178.41 $35K
Oct 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 155 $180.01 $28K
Oct 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 92 $181.18 $17K
Sep 23, 2025 JA Jason Aryeh - Director Open-market sale Common Stock 4,418 $170.41 $753K
Sep 23, 2025 JA Jason Aryeh - Director Open-market sale Common Stock 4,628 $170.96 $791K
Sep 23, 2025 JA Jason Aryeh - Director Open-market sale Common Stock 954 $171.92 $164K
Sep 22, 2025 MZ Martine Zimmermann - Director Tax withholding / forfeiture Common Stock 115 $170.77 $20K
Sep 2, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 267 $161.51 $43K
Sep 2, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 115 $162.52 $19K
Sep 2, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 85 $164.25 $14K
Aug 10, 2025 AR Andrew Reardon - Officer Tax withholding / forfeiture Common Stock 1,325 $150.06 $199K
Aug 1, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 467 $131.88 $62K
Jul 10, 2025 JK John W. Kozarich - Director Open-market sale Common Stock 934 $125.00 $117K
Jun 30, 2025 TD Todd C. Davis - Officer Other Common Stock 233 $91.08 $21K
Jun 6, 2025 JL John L. Lamattina - Director Grant or award Non-Qualified Stock Option (right to buy) 5,783 $0.00 -
Jun 6, 2025 JK John W. Kozarich - Director Grant or award Non-Qualified Stock Option (right to buy) 5,783 $0.00 -
Jan 17, 2025 JK John W. Kozarich - Director Option exercise Common Stock 2,406 $52.30 $126K
Jan 17, 2025 JK John W. Kozarich - Director Option exercise Non-Qualified Stock Option (right to buy) 2,406 $0.00 -
Dec 23, 2024 OE Octavio Espinoza - Officer Open-market sale Common Stock 2,104 $116.37 $245K
Dec 5, 2024 OE Octavio Espinoza - Officer Tax withholding / forfeiture Common Stock 1,859 $123.51 $230K
Nov 27, 2024 JL John L. Lamattina - Director Option exercise Common Stock 2,406 $52.30 $126K
Nov 27, 2024 JL John L. Lamattina - Director Open-market sale Common Stock 2,406 $123.65 $298K
Nov 27, 2024 JL John L. Lamattina - Director Option exercise Non-Qualified Stock Option (right to buy) 2,406 $0.00 -
$LNSR
LENSAR, Inc.
$IONS
IONIS PHARMACEUTICALS INC
